INFECTIOUS DISEASES
GLOBAL CLINICAL TRIAL LANDSCAPE (2025)

#DYK
Did you know?

The **infectious disease clinical trials market**, valued at **$7B (2023), will exceed $13B by 2032** (7% CAGR)

2032
$13B
(7% CAGR)

2023
$7B

Biologics:
67% of trials, including vaccines and monoclonal antibodies

Small Molecules:
31%, covering antivirals and antibiotics

Oligonucleotide Therapies:
2%, focusing on siRNA-based treatments



Key Trial Areas, Viral Infections:
COVID-19, HIV/AIDS, Hepatitis B, RSV, Influenza

Other Key Trial Focus Areas:
Pneumonia, mycoses, bacterial (Mycobacterium, Clostridium), and protozoal infections

Global Impact: 14M deaths yearly, LMICs hit hardest

Emerging Threats: SARS-CoV-2 variants, monkeypox, Lassa fever

NTDs: Schistosomiasis, leishmaniasis, and dengue affect 1B+, underfunded and under-researched

AMR Risk: 10M deaths annually by 2050

Innovations: mRNA, gene editing, DCTs drive trials

Preparedness: Platform trials, AI, regulatory harmonization boost health security

RAPID GROWTH:
~2,000 industry-led infectious disease trials (2020–2024, ~64% CAGR)



Asia-Pacific (43%), driven by China, Japan, Australia, and India

North America (21%) led by the U.S

Europe (20%) led by UK, Germany, and Spain

ROW (16%) with contributions from South Africa and Brazil

Top Countries:
China, U.S, UK

40% **Phase II**

30% **Phase I**

30% **Phase III**